Jerusalem, 20 October, 2025 (TPS-IL) — Israeli company RedHill Biopharma announced Monday that U.S.-based Cumberland Pharmaceuticals will invest $4 million for a 30% stake and joint control in RedHill’s Talicia business. The two firms will co-commercialize Talicia in the United States, sharing revenues and operational responsibilities. RedHill will retain 70% ownership while benefiting from Cumberland’s national sales and marketing network.
The agreement is expected to boost Talicia’s market growth and strengthen RedHill’s financial position as it works to maintain Nasdaq compliance. Talicia is the only FDA-approved all-in-one rifabutin-based therapy for H. pylori, one of the wordl’s most common bacterial infections.